TABLE 5.
Clinical and biochemical characteristics based on N‐acetyl‐seryl‐aspartyl‐lysyl‐proline level in lisinopril‐treated patients
| Ac‐SDKP < 5nM | Ac‐SDKP > 5 nM | p‐value | |
|---|---|---|---|
| N | 11 | 25 | |
| Age (years) | 47.2 ± 2.8 | 49.3 ± 7.2 | .60 |
| Female (%) | 27.3 | 52.0 | .28 |
| BMI (kg/m2) | 34.6 ± 5.2 | 35.3 ± 7.8 | .77 |
| SBP basal (mmHg) | 131.0 ± 9.2 | 129 ± 15.7 | .26 |
| DBP basal (mmHg) | 84.4 ± 7 | 87.1 ± 9.8 | .35 |
| SBP at one year (mmHg) | ‐32.1 ± 25.7 | ‐37.5 ± 23.2 | .56 |
| DBP at one year (mmHg) | ‐17.4 ± 14.5 | ‐17.3 ± 11.82 | 1.00 |
| LVMI at one year (g/m2) | 83.3 ± 9.9 | 79.7 ± 13.8 | .38 |
| Pulse Wave Velocity (m/s) | 7.34 ± 2.9 | 6.19 ± 3.3 | .34 |
| PICP/CITP ratio | 52.6 ± 38 | 43.9 ± 47.2 | .31 |
| PICP (nM) | 75.9 ± 17 | 89.3 ± 31.6 | .25 |
| CITP (nM) | 2.5 ± 2.6 | 3.6 ± 3.1 | .07 |
| MMP1/TIMP1 ratio | 0.038 ± 0.032 | 0.038 ± 0.031 | 1.00 |
| MMP‐1 (nM) | 5.4 ± 4.6 | 5.5 ± 3.8 | .90 |
| TIMP‐1 (nM) | 139.9 ± 27.1 | 161.7 ± 35.9 | .06 |
| Log CITP/MMP‐1 ratio | 0.61 ± 4.76 | 0.76 ± 4.01 | .57 |
| Ac‐SDKP (nM) | 4.05 ± 0.89 | 7.27 ± 2.79 | <0.001 |
Abbreviations: Ac‐SDKP, N‐acetyl‐seryl‐aspartyl‐lysyl‐proline; CITP, telopeptide of collagen type I; MMP‐1, matrix metalloproteinase‐1; PICP, type 1 procollagen C‐terminal propeptide; TIMP‐1, tissue inhibitor of metalloproteinases 1.